rss
J Clin Pathol 2007;60:824-830 doi:10.1136/jcp.2005.036038
  • Original article

Loss of MSH2 protein expression is a risk factor in early stage cervical cancer

  1. E R Nijhuis1,
  2. H W Nijman1,
  3. K A Oien4,
  4. A Bell5,
  5. K A ten Hoor1,
  6. N Reesink-Peters1,
  7. H M Boezen3,
  8. H Hollema2,
  9. A G J van der Zee1
  1. 1Department of Gynecological Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands
  2. 2Department of Pathology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands
  3. 3Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands
  4. 4Department of Pathology, University of Glasgow, Glasgow, UK
  5. 5Department of Pathology, Western Infirmary, Glasgow, UK
  1. Correspondence to:
 Dr A G J van der Zee
 Department of Gynaecologic Oncology, University Medical Centre Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands; a.g.j.van.der.zee{at}og.umcg.nl
  • Accepted 26 July 2006

Abstract

Background: Loss of mismatch repair (MMR) gene expression has been associated with fewer metastases and improved prognosis in various tumour types.

Aims: To evaluate the predictive and prognostic significance of loss of MMR protein MSH2 in early stage cervical cancer.

Methods: Specimens from 218 consecutive patients with early stage, surgically treated cervical cancer were analysed. Median age was 42 years (interquartile range 35–53). International Federation of Gynecology and Obstetrics (FIGO) stages were IB1 (57%), IB2 (25%) and IIA (18%). Histology was 70% squamous cell, 6% adenosquamous and 24% adenocarcinoma. Pelvic lymph node metastasis was present in 66 (30%) patients. Median follow-up was 5.2 years (interquartile range 2.5–7.9). Tissue microarrays (TMAs) were constructed containing three cores of paraffin-embedded tumour per case. MSH2 expression was assessed by immunohistochemistry on TMAs and full sections.

Results: In TMAs MSH2 expression could be analysed in 184/218 (84%) tumours. Loss of MSH2 was observed in 58/184 (32%) tumours, with a moderately strong concordance between TMAs and full sections (κ = 0.47). In tumours with loss of MSH2, pelvic lymph node metastasis and cancer invasion beyond 10 mm were more frequent (48% vs 25%, and 59% vs 37%, respectively). However, loss of MSH2 expression was not related to recurrence or survival.

Conclusion: TMAs are powerful tools for high throughput screening of biological markers for prognostic value in cervical cancer. Absence of MSH2 expression is associated with a high-risk profile in early stage cervical cancer, but does not predict lymph node status with sufficient accuracy to be used in the clinic.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.